New Delhi : Drug firm Dr Reddy’s Laboratories said it has launched in the US generic Paricalcitol injection used for treatment associated with chronic kidney disease.
It has launched the injection USP in the strengths of 2 mcg, 5 mcg and 10 mcg, Dr Reddy’s Laboratories said in a filing to BSE.
The company’s product is generic version of AbbVie Inc’s Zemplar injections, it added.
The injection is first Abbreviated New Drug Application (ANDA) product launched in the US after approval from the US Food and Drug Administration, it said.
Zemplar is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure.
Dr Reddy’s said: “The Zemplar brand and generic had US sales of approximately USD 22.5 million MAT for the most recent 12 months ending July 2016 according to IMS Health.”